Anupam Rasayan to Acquire Up to 48.2% Stake in Bliss GVS Pharma Alongside Open Offer 

Key Highlights: 

• Anupam Rasayan India has entered into a definitive agreement to acquire a 43.3%–48.2% equity stake in Bliss GVS Pharma, an India-based pharmaceutical formulations company. In addition to the stake acquisition, Anupam Rasayan will also launch an open offer to acquire shares from public shareholders in accordance with regulatory requirements 

• The transaction marks Anupam Rasayan’s strategic expansion beyond specialty chemicals into the pharmaceutical formulations segment, strengthening its presence across the broader healthcare value chain. Bliss GVS Pharma operates across multiple therapeutic areas and has an established footprint in domestic and international pharmaceutical markets 

• The acquisition will be financed through a combination of ₹300Cr term loan funding and non-controlling, non-voting equity instruments for the remaining consideration. Through the deal, Anupam Rasayan aims to enhance long-term growth opportunities, diversify its business portfolio, and leverage synergies between specialty chemicals and pharmaceutical manufacturing capabilities 

Implications: 

This is a strategic diversification move: Anupam Rasayan is using Bliss GVS to enter pharmaceutical formulations and move further up the healthcare value chain. The deal could broaden its revenue base, but it also introduces integration and execution risk as it shifts beyond specialty chemicals.  

Source: Anupam Rasayan